Allergan PLC. Company Profile (NYSE:AGN)

About Allergan PLC. (NYSE:AGN)

Allergan PLC. logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:AGN
  • CUSIP: 01849010
  • Web:
  • Market Cap: $83.6544 billion
  • Outstanding Shares: 335,867,000
Average Prices:
  • 50 Day Moving Avg: $239.66
  • 200 Day Moving Avg: $234.93
  • 52 Week Range: $184.50 - $261.27
  • Trailing P/E Ratio: 7.82
  • Foreward P/E Ratio: 13.93
  • P/E Growth: 1.16
Sales & Book Value:
  • Annual Revenue: $14.74 billion
  • Price / Sales: 5.72
  • Book Value: $209.35 per share
  • Price / Book: 1.20
  • Annual Dividend: $2.80
  • Dividend Yield: 1.1%
  • EBIDTA: $5.8 billion
  • Net Margins: 82.42%
  • Return on Equity: 7.29%
  • Return on Assets: 4.08%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 1.32%
  • Quick Ratio: 1.23%
  • Average Volume: 2.21 million shs.
  • Beta: 1.16
  • Short Ratio: 2.45
Frequently Asked Questions for Allergan PLC. (NYSE:AGN)

What is Allergan PLC.'s stock symbol?

Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?

Allergan PLC. declared a quarterly dividend on Friday, May 5th. Investors of record on Thursday, May 18th will be given a dividend of $0.70 per share on Thursday, June 15th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date is Tuesday, May 16th. View Allergan PLC.'s Dividend History.

How were Allergan PLC.'s earnings last quarter?

Allergan PLC. (NYSE:AGN) announced its quarterly earnings data on Tuesday, May, 9th. The company reported $3.35 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.32 by $0.03. The business earned $3.57 billion during the quarter, compared to analysts' expectations of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.04 EPS. View Allergan PLC.'s Earnings History.

When will Allergan PLC. make its next earnings announcement?

Allergan PLC. is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Allergan PLC..

What guidance has Allergan PLC. issued on next quarter's earnings?

Allergan PLC. updated its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus estimate of $16.01.

Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?

17 brokerages have issued 1 year price targets for Allergan PLC.'s stock. Their predictions range from $231.00 to $400.00. On average, they anticipate Allergan PLC.'s share price to reach $275.88 in the next year. View Analyst Ratings for Allergan PLC..

What are analysts saying about Allergan PLC. stock?

Here are some recent quotes from research analysts about Allergan PLC. stock:

  • 1. According to Zacks Investment Research, "Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (7/11/2017)
  • 2. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan PLC.'s key competitors?

Who owns Allergan PLC. stock?

Allergan PLC.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include Factory Mutual Insurance Co. (0.15%), APG Asset Management N.V. (0.14%), Swedbank (0.10%), Confluence Investment Management LLC (0.09%), Chevy Chase Trust Holdings Inc. (0.09%) and Intermede Investment Partners Ltd (0.08%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..

Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?

Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Swedbank, OLD National Bancorp IN, Armstrong Shaw Associates Inc. CT, Winslow Evans & Crocker Inc., Chemung Canal Trust Co., Exxonmobil Investment Management Inc. TX and Factory Mutual Insurance Co.. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?

Allergan PLC.'s stock was bought by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., Mn Services Vermogensbeheer B.V., Intermede Investment Partners Ltd, Confluence Investment Management LLC, Pennsylvania Trust Co, AMI Asset Management Corp, Oakbrook Investments LLC and Aperio Group LLC. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

How do I buy Allergan PLC. stock?

Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan PLC.'s stock price today?

One share of Allergan PLC. stock can currently be purchased for approximately $250.97.

MarketBeat Community Rating for Allergan PLC. (NYSE AGN)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  820 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  1,163
MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $275.88 (9.92% upside)

Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Credit Suisse Group AGReiterated RatingOutperform$274.00 -> $286.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$265.00 -> $273.00MediumView Rating Details
7/16/2017Royal Bank Of CanadaSet Price TargetBuy$284.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$231.00LowView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral -> Neutral$231.00LowView Rating Details
6/9/2017MizuhoLower Price TargetBuy -> Buy$275.00 -> $267.00MediumView Rating Details
6/8/2017Cowen and CompanySet Price TargetBuy$400.00MediumView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/10/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$262.00HighView Rating Details
4/24/2017Citigroup Inc.Boost Price TargetBuy$261.00LowView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
12/23/2016Bank of America CorporationReiterated RatingBuy$280.00N/AView Rating Details
12/6/2016ArgusReiterated RatingBuy$340.00 -> $260.00N/AView Rating Details
12/5/2016J P Morgan Chase & CoSet Price TargetBuy$300.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Morgan StanleyLower Price TargetOverweight$300.00 -> $274.00N/AView Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00N/AView Rating Details
6/10/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Allergan PLC. (NYSE:AGN)
Earnings by Quarter for Allergan PLC. (NYSE:AGN)
Earnings History by Quarter for Allergan PLC. (NYSE AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017$3.93N/AView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$4.00$4.07$4.04
Q3 20172$4.09$4.16$4.13
Q4 20172$4.52$4.67$4.60
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC. (NYSE:AGN)
Most Recent Dividend:6/15/2017
Annual Dividend:$2.80
Dividend Yield:1.12%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:9.63% (Trailing 12 Months of Earnings)
17.42% (Based on This Year's Estimates)
15.54% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan PLC. (NYSE:AGN)

Dividend History by Quarter for Allergan PLC. (NYSE AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 84.53%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
DateHeadline logoSOL Capital Management CO Buys PIMCO Enhanced Short Maturity Active Exchange-Trad, Vanguard ... - July 22 at 8:36 PM logoAllergan PLC. (NYSE:AGN) Earns Outperform Rating from Credit Suisse Group - July 20 at 9:06 AM logoEquities Analysts Offer Predictions for Allergan PLC.'s Q2 2017 Earnings (AGN) - July 20 at 8:16 AM logoTechnical Reports on Generic Drugs Equities -- Allergan, Ironwood Pharma, Medicines Co., and Catalent - PR Newswire (press release) - July 19 at 4:35 PM logoAllergan (AGN) Appoints Joseph Boccuzi to Board - - July 19 at 4:35 PM logoQ4 2017 EPS Estimates for Allergan PLC. Raised by Analyst (NYSE:AGN) - July 19 at 12:38 PM logoHead-To-Head Analysis: NephroGenex (NRX) vs. Allergan PLC. (AGN) - July 19 at 8:51 AM logoNoteworthy ETF Inflows: PFF, AGN, HSBC, DB - Nasdaq - July 18 at 4:45 PM logoHow Allergan’s US Specialized Therapeutics Segment Performed - July 18 at 2:04 AM logoAllergan PLC. (NYSE:AGN) Given Average Rating of "Buy" by Brokerages - July 18 at 12:48 AM logoAllergan PLC. (NYSE:AGN) Stock Rating Reaffirmed by Deutsche Bank AG - July 17 at 9:02 PM logoNoteworthy Monday Option Activity: VHC, AGN, BIIB - Nasdaq - July 17 at 3:58 PM logoInside Allergan’s International Business - July 17 at 3:58 PM logoValeant Unloads Yet Another Unit - July 17 at 3:58 PM logoAllergan PLC. (AGN) Stock Rating Reaffirmed by Royal Bank Of Canada - July 16 at 7:32 AM logoAllergan PLC. (NYSE:AGN) Rating Reiterated by Piper Jaffray Companies - July 15 at 10:16 AM logoWhat Allergan’s Valuation as of July 13 Tells Us - July 14 at 5:25 PM logoUnderstanding Allergan’s Revenue Stream for 2017 - July 14 at 5:25 PM logoBehind Allergan’s Business Segments and Revenues - July 14 at 5:25 PM logoAmgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab) - July 13 at 4:19 PM logoAllergan Lends Support to Broaden Uterine Fibroid Awareness Month - July 13 at 4:19 PM logoCredit Suisse likes Allergan, sees 12% upside - Seeking Alpha - July 12 at 4:02 PM logoZacks: Analysts Anticipate Allergan PLC. (NYSE:AGN) Will Announce Quarterly Sales of $3.96 Billion - July 12 at 9:51 AM logoAllergan PLC. (AGN) Stock Rating Upgraded by Zacks Investment Research - July 11 at 10:14 PM logoAllergan Reports Positive New Data on Irritable Bowl Drug - July 11 at 4:47 PM logoA Look at Allergan’s Performance in 2Q17 - July 11 at 4:47 PM logoZacks: Brokerages Expect Allergan PLC. (NYSE:AGN) to Post $3.98 EPS - July 10 at 6:18 PM logoAllergan (AGN) Says New Data Reinforces Effectiveness of Viberzi ... - - July 10 at 3:19 PM logoToo Early To Roll The Dice With Allergan - Seeking Alpha - July 10 at 3:19 PM logoUK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents - - July 7 at 5:34 PM logoAllergan, Celgene Offer Solid Biotech Value - July 7 at 5:33 PM logo10 Attractively Valued Stocks With Competitive Edge - July 5 at 9:10 PM logoAllergan PLC. (AGN) to Post FY2017 Earnings of $16.07 Per Share, Cantor Fitzgerald Forecasts - July 3 at 9:04 AM logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Allergan, Inc. - July 1 at 1:52 AM logo[$$] Oklahoma Sues Opioid Painkiller Makers - June 30 at 3:43 PM logoSecurities Class Action Filed on Behalf of Persons or Entities That Traded Certain Derivative Securities of Allergan, Inc. During the Period February 25, 2014 Through April 21, 2014, Inclusive - June 30 at 3:43 PM logoOklahoma sues opioid drugmakers; New Hampshire presses epidemic probe - June 30 at 3:43 PM logoCritical Review: Allergan PLC. (AGN) and NephroGenex (NRX) - June 30 at 9:09 AM logoSarepta appoints former Allergan executive Douglas Ingram as CEO - Nasdaq - June 29 at 1:53 AM logoNotable ETF Inflow Detected - VHT, GILD, LLY, AGN - June 28 at 3:50 PM logoAllergan Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest Innovation in the REFRESH® Portfolio - June 27 at 3:29 PM logoBill Ackman's Big Triumph Becomes His Big Problem - June 27 at 3:29 PM logoValeant: Out of the Frying Pan, Into the Fire - June 27 at 3:29 PM logoAllergan PLC. (AGN) Lifted to Buy at BidaskClub - June 24 at 9:06 PM logoStock Traders Purchase High Volume of Allergan PLC. Put Options (AGN) - June 23 at 12:37 PM logoInvestors Purchase Large Volume of Allergan PLC. Call Options (AGN) - June 22 at 12:32 PM logoMissouri sues opioid manufacturers, joining two other U.S. states - June 21 at 4:10 PM logoTodd Hagopian's Top 2 Mental Health Biotech Stocks - June 21 at 4:10 PM logoAllergan PLC. (AGN) Receives Consensus Recommendation of "Buy" from Brokerages - June 21 at 12:38 AM logoAllergan Is Putting the Bull Back in Charge - June 19 at 3:27 PM



Allergan PLC. (AGN) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff